查看文章

BNCT as a treatment for glioblastoma multiforme and melanoma. Successful BNCT depends on knowledge of the distribution of boron-containing agents in both tumor and normal tissue as cur rently determined by chemical confirmation of boron deposition in surgically removed malignant tissue before BNCT. We used PET to noninvasively obtain in vivo information on the pharmacokinetics of the 18F-labeled analog of BPA-Fr in two patients with glioblastoma multiforme. Time-activity curves generated from the bolus injection of 18F-BPA-Fr were convolved to simulate a continuous infusion used for BNCT therapy. Distribution of 18F-BPA-Fr by PET was found to be consistent with tumor as identified by MR imaging. The18F-BPA-Fr tumor-to-normal brain uptake ratio was 1.9 in Patient 1 and 3.1 in Patient 2 at 52 min after injection. The 18F-BPA-Fr uptake ratio in glioblastoma paralleled that of …